Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endosurgery-02: Neoadjuvant Chemoimmunotherapy and Endoscopic Resection for Esophageal Cancer
NCT07317609Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Organ preservation rate up to 12 months, Incidence of Grade >=3 adverse events up to 30 days and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07317609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317609.